• Home

  • Documents

  •  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21...
19

 · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20

  • Upload
    others

  • View
    5

  • Download
    0

Embed Size (px)

Citation preview

Page 1:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 2:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 3:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 4:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 5:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 6:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 7:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 8:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 9:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 10:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 11:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 12:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 13:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 14:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 15:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 16:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 17:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 18:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20
Page 19:  · Gefitinib Gefitinib 1. Non-small cell lung cancer EGFR DNA EGF-R exon 19 deletion, exon 21 [1.858R] substitution mutations, L861Q G719X EGFR exon 20

Gefitinib Iressa Anticancer Medicine

Gefitinib Iressa Anticancer Medicine

Documents
DESIGN AND SYNTHESIS OF NEW EGFR - TYROSINE …applications.emro.who.int/imemrf/Bull_Pharm_Sci_Assiut_Univ/Bull... · Rania B. Bakr, et al. 28 O O O O Erlotinib I Gefitinib II N N

DESIGN AND SYNTHESIS OF NEW EGFR - TYROSINE …applications.emro.who.int/imemrf/Bull_Pharm_Sci_Assiut_Univ/Bull... · Rania B. Bakr, et al. 28 O O O O Erlotinib I Gefitinib II N N

Documents
Biosensors and Bioelectronics - KAISTbel.kaist.ac.kr/extfiles/papers/20150827.pdf · Comprehensive detection of diverse exon 19 deletion mutations of EGFR in lung Cancer by a single

Biosensors and Bioelectronics - KAISTbel.kaist.ac.kr/extfiles/papers/20150827.pdf · Comprehensive detection of diverse exon 19 deletion mutations of EGFR in lung Cancer by a single

Documents
Therapeutic Advances in Medical Oncology › sites › default › files... · egfr egfr egfr egfr egfr nsclc. egfr egfr

Therapeutic Advances in Medical Oncology › sites › default › files... · egfr egfr egfr egfr egfr nsclc. egfr egfr

Documents
NSCLC Progress in the treatment Optimal Treatment with EGFR-TKI Therapy Gefitinib vs. Erlotinib 蔡 俊 明 Chun-Ming Tsai, MD Section of Thoracic Oncology Chest

NSCLC Progress in the treatment Optimal Treatment with EGFR-TKI Therapy Gefitinib vs. Erlotinib 蔡 俊 明 Chun-Ming Tsai, MD Section of Thoracic Oncology Chest

Documents
GPR119 agonist enhances gefitinib responsiveness through

GPR119 agonist enhances gefitinib responsiveness through

Documents
Next Generation EGFR Inhibitors - Amazon S3 · The Chinese University of Hong Kong. EGFR TKIs First Generation-Gefitinib ... Osimertinib approved by FDA on Nov 13, ... Yang et al

Next Generation EGFR Inhibitors - Amazon S3 · The Chinese University of Hong Kong. EGFR TKIs First Generation-Gefitinib ... Osimertinib approved by FDA on Nov 13, ... Yang et al

Documents
Gefitinib Brands Medicine Online

Gefitinib Brands Medicine Online

Healthcare
Molecular Cancer - RESEARCH Open Access Synergistic ......EGFR, including low molecular weight tyrosine kinase inhibitors [22]. Gefitinib (Iressa, ZD-1839) acts as a competitive inhibitor

Molecular Cancer - RESEARCH Open Access Synergistic ......EGFR, including low molecular weight tyrosine kinase inhibitors [22]. Gefitinib (Iressa, ZD-1839) acts as a competitive inhibitor

Documents
The challenge of targeting EGFR: experience with …...REVIEW The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer A.A. Armour and C.L. Watkins ABSTRACT:

The challenge of targeting EGFR: experience with …...REVIEW The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer A.A. Armour and C.L. Watkins ABSTRACT:

Documents
NSCLC overview - OverGroupEGFR-TKIs I line treatment of EGFR mutated NSCLC patients STUDIO TERAPIA PZ 0RR (%) PFS (m)IPASS Gefitinib vs CBDCA+Tax 261 71.2 vs 47.3 9.8 vs 6.4 First-Signal

NSCLC overview - OverGroupEGFR-TKIs I line treatment of EGFR mutated NSCLC patients STUDIO TERAPIA PZ 0RR (%) PFS (m)IPASS Gefitinib vs CBDCA+Tax 261 71.2 vs 47.3 9.8 vs 6.4 First-Signal

Documents
ClinicalStudy - Hindawi Publishing Corporationdownloads.hindawi.com/archive/2017/8196434.pdf · ChemotherapyResearchandPractice 3 Exon 19-censored Exon 21-censored Exon 19 Exon 21

ClinicalStudy - Hindawi Publishing Corporationdownloads.hindawi.com/archive/2017/8196434.pdf · ChemotherapyResearchandPractice 3 Exon 19-censored Exon 21-censored Exon 19 Exon 21

Documents
PRODUCT MONOGRAPH NAT-Gefitinib

PRODUCT MONOGRAPH NAT-Gefitinib

Documents
Quality of Life with Gefitinib in Patients with EGFR

Quality of Life with Gefitinib in Patients with EGFR

Documents
cobas EGFR Mutation Test v2 · 2016-06-06 · cobas ® EGFR Mutation Test v2 07384351001-02EN Doc. Rev. 2.0 7 . mutations in exon 18, deletion mutations in exon 19, T790M and S768I

cobas EGFR Mutation Test v2 · 2016-06-06 · cobas ® EGFR Mutation Test v2 07384351001-02EN Doc. Rev. 2.0 7 . mutations in exon 18, deletion mutations in exon 19, T790M and S768I

Documents
GENEFLASH - · PDF filePilihan Terapi Oleh Najmiatul ... gen EGFR terletak pada domain kinase tirosin, umumnya berupa in-frame deletion pada exon 19 dan ... HIV, dan sebagainya

GENEFLASH - · PDF filePilihan Terapi Oleh Najmiatul ... gen EGFR terletak pada domain kinase tirosin, umumnya berupa in-frame deletion pada exon 19 dan ... HIV, dan sebagainya

Documents
EGFR exon 20 insertion mutations and response to osimertinib in … · 2019. 8. 15. · NSCLC cases. The most frequently identified EGFRexon20ins is A767_V769dup (17/53,32.1%). We

EGFR exon 20 insertion mutations and response to osimertinib in … · 2019. 8. 15. · NSCLC cases. The most frequently identified EGFRexon20ins is A767_V769dup (17/53,32.1%). We

Documents
AstraZeneca Pharmaceuticals LP IRESSA- gefitinib tablet

AstraZeneca Pharmaceuticals LP IRESSA- gefitinib tablet

Documents
First-line afatinib vs gefitinib for patients with EGFR ... · ORIGINAL ARTICLE - CLINICAL ONCOLOGY First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC

First-line afatinib vs gefitinib for patients with EGFR ... · ORIGINAL ARTICLE - CLINICAL ONCOLOGY First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC

Documents
OPTIMIZACIÓN TRATAMIENTO ANTI-EGFR · KRAS exon 2 wt population1 0 6 12 18 24 30 36 42 48 54 28.4 20.2 0.0 0.2 0.6 0.8 ... Benefit with anti-EGFR Benefit without anti-EGFR Choice

OPTIMIZACIÓN TRATAMIENTO ANTI-EGFR · KRAS exon 2 wt population1 0 6 12 18 24 30 36 42 48 54 28.4 20.2 0.0 0.2 0.6 0.8 ... Benefit with anti-EGFR Benefit without anti-EGFR Choice

Documents
EGFR exon 20 insertion mutations and response to ... · mutations within the EGFR mutant lung cancer is incon-sistent, contributing to roughly 4–12% of all EGFR muta-tions identified

EGFR exon 20 insertion mutations and response to ... · mutations within the EGFR mutant lung cancer is incon-sistent, contributing to roughly 4–12% of all EGFR muta-tions identified

Documents
Teràpies diana: fer un bon ús dels biomarcadors i del ...€¦ · Gefitinib EGFR mutation Erlotinib EGFR mutation Crizotinib Vemurafenib Imatinib Biomarker ... EGFR S492R (% of

Teràpies diana: fer un bon ús dels biomarcadors i del ...€¦ · Gefitinib EGFR mutation Erlotinib EGFR mutation Crizotinib Vemurafenib Imatinib Biomarker ... EGFR S492R (% of

Documents
Next-Generation EGFR Tyrosine Kinase Inhibitors for ... · gefitinib in the first-line treatment of patients with EGFR-mutant NSCLC (15). Unfortunately, the majority of patients progress

Next-Generation EGFR Tyrosine Kinase Inhibitors for ... · gefitinib in the first-line treatment of patients with EGFR-mutant NSCLC (15). Unfortunately, the majority of patients progress

Documents
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon ......Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer Francois

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon ......Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer Francois

Documents
Tyrosine kinase inhibitors for solid tumors in the past 20 years … · 2020. 10. 27. · TAK-788 (mobocertinib) - Takeda EGFR, HER2 Metastatic NSCLC with EGFR exon 20 inser-tions

Tyrosine kinase inhibitors for solid tumors in the past 20 years … · 2020. 10. 27. · TAK-788 (mobocertinib) - Takeda EGFR, HER2 Metastatic NSCLC with EGFR exon 20 inser-tions

Documents
Bases genéticas y moleculares del síndrome de … · Bases genéticas y moleculares del síndrome de Brugada 297 Exon 28 Exon 9 ¿Mutación? Exon 28 Exon 28 Exon 9 V2 V2 Figura

Bases genéticas y moleculares del síndrome de … · Bases genéticas y moleculares del síndrome de Brugada 297 Exon 28 Exon 9 ¿Mutación? Exon 28 Exon 28 Exon 9 V2 V2 Figura

Documents
PowerPoint Presentation · Retinoblastoma WT QRX-421 Exon 12 Exon 13 Exon 14 Exon 12 Exon 14 In-frame Exon 11 Exon 14 Out of-frame No AON QRX-421 Exon 12 Exon 13 Exon 14 Erwin van

PowerPoint Presentation · Retinoblastoma WT QRX-421 Exon 12 Exon 13 Exon 14 Exon 12 Exon 14 In-frame Exon 11 Exon 14 Out of-frame No AON QRX-421 Exon 12 Exon 13 Exon 14 Erwin van

Documents
NF-κB–driven suppression of FOXO3a contributes to … · NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance Ching-Feng Chiua,1,

NF-κB–driven suppression of FOXO3a contributes to … · NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance Ching-Feng Chiua,1,

Documents
exon 19 deletion (T751 I759>S) Gilotrif® (Afatinib) SAMPLE · 2020. 3. 26. · EGFR exon 19 deletion (T751_I759>S) CDx Associated Findings GENOMIC FINDINGS DETECTED FDFDAA-APPR-APPROOVED

exon 19 deletion (T751 I759>S) Gilotrif® (Afatinib) SAMPLE · 2020. 3. 26. · EGFR exon 19 deletion (T751_I759>S) CDx Associated Findings GENOMIC FINDINGS DETECTED FDFDAA-APPR-APPROOVED

Documents
What Should Physician Assistants Know about Genetics ... · 4/5/2001  · Cancer • familial • sporadic. ... Genomic Analysis. EGFr Mutation and Gefitinib Sensitivity in NSC Lung

What Should Physician Assistants Know about Genetics ... · 4/5/2001  · Cancer • familial • sporadic. ... Genomic Analysis. EGFr Mutation and Gefitinib Sensitivity in NSC Lung

Documents